Brad Sitko, CIO, XOMA Royalty | Onyx Live | JPM 2026
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
JPM 2026
Avi Veidman, CEO, Nucleai | Onyx Live | JPM 2026
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will biotech still be relevant in 2030? | Treehill Partners Ep. 3 | JPM 2026
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
Mike Cordonnier, CEO, Carlsmed | Onyx Live | JPM 2026
Hundreds of thousands of spine fusions are performed each year, but implant choice is still often limited to standard sizes.
Chris Hall, CEO, Personalis | Onyx Live | JPM 2026
Personalis is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.
Adrian Gottschalk, CEO, Foghorn Therapeutics | Onyx Live | JPM 2026
The machinery that governs gene expression is being targeted to beat cancer.
Nara Daubeney and Piers Daubeney, CEO and Co-Founder, Phaim | Onyx Live | JPM 2026
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
Daniel Green, CEO, eSpraye | JPM 2026
If the disease is in the lungs, why deliver the drugs everywhere else?
Fabian Gerlinghaus, CEO, Cellares | Onyx Live | JPM 2026
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
Stefan Scherer, CEO, 3T Biosciences | JPM 2026
Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital?
Nick Delmonico, CEO, Strados Labs | Onyx Live | JPM 2026
1 in 5 patients hospitalized with COPD are readmitted within 30 days of discharge - costing the US over $15 billion. But why?
Coverage sponsored by
Jefferies 2025
Jefferies Healthcare Conference 2025 - Onyx Roundup | London Life Sciences Week 2025
Capital is available, but only for companies with clean data, clear differentiation, and a believable commercial path.
Onyx @ Jefferies: Lubor Gaal, CFO, Circio
A fully funded pharma study plus multiple R&D collaborations signals rising strategic pull.
Onyx @ Jefferies: David Chang, CEO, Allogene
Cema-cel is already in the pivotal Phase 2 ALPHA3 frontline lymphoma trial, with manufacturing capacity sized for tens of thousands of annual doses (up to ~60,000 across products).
Onyx @ Jefferies: Jon Rees, CEO, MitoRx
The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
Onyx @ Jefferies: Ali Pashazadeh, CEO, Treehill Partners
"85% of failures are us having failed the molecule, not the molecule having not delivered."
Onyx @ Jefferies: David Hung, CEO, Nuvation Bio
Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer.
JPM 2025
Adil's JPM Week VLOG
Join me in San Fran as I interview CEOs and reveal what Onyx has in store for readers this year.
Onyx @ Union Square: Colleen Cutcliffe, CEO, Pendulum
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
Onyx @ Union Square: Helmy Eltoukhy, CEO, Guardant Health
Blood tests for cancer are here, and Guardant Health is leading the charge.
Onyx @ Union Square: Mike Exton, CEO, Lexicon Pharmaceuticals
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
Onyx @ Union Square: Shankar Musunuri, CEO, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Onyx Studio Sessions
Onyx Studio Sessions: Paula Brown Stafford, CEO, Allucent
Allucent is a CRO which has overseen many therapeutics through to FDA approval.
Onyx Studio Sessions: Fabian Gerlinghaus, CEO, Cellares
Can Cellares bring down the cost of some of the most expensive new therapies on the market?
Onyx Explains
How India is leading a cancer revolution
The story of how an Indian biotech startup slashed the cost of CAR-T from $475,000 to just $30,000 and started a revolution in global CAR-T therapy access.